A AND G PHARMACEUTICAL, INC.

Basic Information

A AND G PHARMACEUTICAL, INC. 9130 RED BRANCH RD, STE U COLUMBIA, MD, 21045-

Company Profile

n/a

Additional Details

Field Value DUNS: 963442723 **Hubzone Owned:** N Socially and Economically Disadvantaged: Ν Woman Owned: Ν Number of Employees: n/a jQuery(document).ready(function() { (function (\$) { var xAxis = ['SBIR PI', 'SBIR PII', 'STTR PI', 'STTR PII']; var yAxis1 = [{"y":7,"ytitle":"SBIR Phase I", "ycount": 7, "yamount": 1110996}, {"y": 2, "ytitle": "SBIR Phase II", "ycount": 2, "yamount": 2632423}, {"y": 0, "ytitle": "STTR Phase $I","ycount":0,"yamount":0\}, \{"y":0,"ytitle":"STTR \ Phase \ II","ycount":0,"yamount":0\}]; \ var \ yAxis2 = I","ycount":0,"yamount":0,"ya$ [{"y":1110996,"ytitle":"SBIR Phase I","ycount":7,"yamount":1110996},{"y":2632423,"ytitle":"SBIR Phase II", "ycount":2, "yamount":2632423}, {"y":0, "ytitle": "STTR Phase I","ycount":0,"yamount":0},{"y":0,"ytitle":"STTR Phase II","ycount":0,"yamount":0}]; //var programAmount = [1110996,2632423,0,0]; var title = 'By Program and Phase'; var titleFormat = 'Count: {point.y:0f}'; var titleFormatAmount = 'Amount: \${point.y:.2f}'; \$('#award-totals-chartcount').highcharts({ chart: { zoomType: 'xy' }, title: { text: title }, xAxis: { categories: xAxis, labels: { rotation: -45, style: { fontSize: '13px', fontFamily: 'Verdana, sans-serif' } }, title: { enabled: true, text: 'Program/Phase' }, crosshair: true }, yAxis: [{ // Primary yAxis min: 0, labels: { style: { color: Highcharts.getOptions().colors[0] } }, title: { text: 'Award Count', style: { color: Highcharts.getOptions().colors[0] } } }, { // Secondary yAxis min: 0, title: { text: 'Award Amount', style: { color: Highcharts.getOptions().colors[1] } }, labels: { style: { color: Highcharts.getOptions().colors[1] } }, opposite: true }], legend: { enabled: false }, tooltip: { shared: false, formatter: function () { return "" + this.point.ytitle + "

Count: "+this.point.ycount+"

Amount: \$"+Highcharts.numberFormat(this.point.yamount,2,'.',')+"
"; } , series: [{ name: 'Award Count', type: 'column', yAxis: 1, data: yAxis1 }, { name: 'Award Amount', type: 'spline', data: yAxis2 }] }); var xAxis =
[2004,2007,2009,2010,2011,2012,2013,2014]; var yAxis1 = [{"y":1,"ytitle":2004,"ycount":1,"yamount":99960},{"y":1,"ytitle":2007,"ycount":1,"yamount":120600},{"y":1,"ytitle":2009,"ycount":1,"yamount":184029},{"y":1,"ytitle":2010,"ycount":1,"yamount":153871},{"y":1,"ytitle":2011,"ycount":1,"yamount":13320},{"y":2,"ytitle":2012,"ycount":2,"yamount":1478552}]; var yAxis2 = [{"y":99960,"ytitle":2004,"ycount":1,"yamount":120600,"ytitle":2007,"ycount":1,"yamount":120600,"ytitle":2007,"ycount":1,"yamount":120600,"y:184029,"ytitle":2009,"ycount":1,"yamount":184029},{"y":153871,"ytitle":2010,"ycount":1,"yamount":113320},{"y":393259,"ytitle":2012,"ycount":2,"yamount":1,"yamount":

A AND G PHARMACEUTICAL, INC. SBIR · STTR Published on SBIR.gov (https://www.sbir.gov)



:1478552,"ytitle":2014,"ycount":1,"yamount":1478552}]; var title = 'By Year'; var titleFormat = 'Count: {point.y:0f}'; var titleFormatAmount = 'Amount: \${point.y:.2f}'; \$('#award-totals-chartcount-year').highcharts({ chart: { zoomType: 'xy' }, title: { text: title }, xAxis: { categories: xAxis, labels: { rotation: -45, style: { fontSize: '13px', fontFamily: 'Verdana, sans-serif' } }, crosshair: true }, yAxis: [{ // Primary yAxis min: 0, labels: { style: { color: Highcharts.getOptions().colors[0] } }, title: { text: 'Award Count', style: { color: Highcharts.getOptions().colors[0] } } }, { // Secondary vAxis min: 0, title: { text: 'Award Amount', style: { color: Highcharts.getOptions().colors[1] } }, labels: { style: { color: Highcharts.getOptions().colors[1] } }, opposite: true }], legend: { enabled: false }, tooltip: { shared: false, formatter: function () { return "" + this.point.ytitle + "

Count: "+this.point.ycount+"

Amount: \$"+Highcharts.numberFormat(this.point.yamount,2,'.',',')+" "; } }, series: [{ name: 'Award Count', type: 'column', yAxis: 1, data: yAxis1 }, { name: 'Award Amount', type: 'spline', data: yAxis2 }] }); var xAxis = ["HHS"]; var yAxis1 = $[{"y":9,"ytitle":"HHS","ycount":9,"yamount":3743419}]; var yAxis2 =$ [{"y":3743419,"ytitle":"HHS","ycount":9,"yamount":3743419}]; var title = 'By Agency'; var titleFormat = 'Count: {point.y:0f}'; var titleFormatAmount = 'Amount: \${point.y:.2f}'; var charWidth = \$('#award-totals-chart-count').width(); charWidth -= 120; \$('#award-totals-chart-countagency').highcharts({ chart: { zoomType: 'xy' }, title: { text: title }, xAxis: { categories: xAxis, labels: { rotation: -45, style: { fontSize: '13px', fontFamily: 'Verdana, sans-serif' } }, crosshair: true }, vAxis: [{ // Primary vAxis min: 0, labels: { style: { color: Highcharts.getOptions().colors[0] } }, title: { text: 'Award Count', style: { color: Highcharts.getOptions().colors[0] } } }, { // Secondary yAxis min: 0, title: { text: 'Award Amount', style: { color: Highcharts.getOptions().colors[1] } }, labels: { style: { color: Highcharts.getOptions().colors[1] } }, opposite: true }], legend: { enabled: false }, tooltip: { shared: false, formatter: function () { return "" + this.point.ytitle + "

Count: "+this.point.ycount+"

Amount: \$"+Highcharts.numberFormat(this.point.yamount,2,'.',',')+" "; } }, series: [{ name: 'Award Count', type: 'column', yAxis: 1, data: yAxis1 }, { name: 'Award Amount', type: 'spline', data: yAxis2 }] }); \$('#award-totals-chart-count-year, #award-totals-chartcount-agency').removeClass('active'); })(jQuery); });

- By Program/Phase
- By Year
- By Agency

Excel

1.

Title: Development of Novel Anticancer Agent to potentiate sensitivity to antiestrogen therapy PoP: 09/19/2014 to 09/18/2016

Amount: \$1,478,552.00

Not Available

SBIR Phase II 2014 Department of Health and Human Services

2.

A AND G PHARMACEUTICAL, INC.

Published on SBIR.gov (https://www.sbir.gov)

IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0

Amount: \$199,828.00

The purpose of this application is to develop realiable, renewable, cost effective, specific, high affinity antipeptide affitnity reagent to be successfully used in mass spec based cancer biomarker de ...

SBIR Phase I 2013 Department of Health and Human Services

3.

<u>Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility</u> Studies

Amount: \$193,879.00

DESCRIPTION (provided by applicant): Lung Cancer remains the leading cause of cancer and mortality for men and women worldwide. In 2010, there were 222,520 new cases of lung cancer diagnosed in t ...

SBIR Phase I 2012 Department of Health and Human Services

4.

NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY

Amount: \$199,380.00

Aromatase Inhibitors (AI) are the preferred hormonal treatment for estrogen receptor positive Breast Cancer (BC) in postmenopausal women and are used to treat approximately 140,000 patients annually i ...

SBIR Phase I 2012 Department of Health and Human Services

5.

<u>Serum GP88 biomarker as a surrogate marker for disease progression in</u> breast canc

Amount: \$113,320.00

DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until ...

SBIR Phase I 2011 Department of Health and Human Services

6.

Novel Targeted Therapy for Breast Cancer

Amount: \$1,153,871.00

DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side eff ...

SBIR Phase II 2010 Department of Health and Human Services

7.

Novel Small Molecule Inhibitor of Rheumatoid Arthritis

Amount: \$184,029.00

DESCRIPTION (provided by applicant): Lck is a Src family non-receptor tyrosine kinase expressed by T lineage lymphocytes. In T cells, Lck plays an essential role in the generation of antigen-mediated ...

SBIR Phase I 2009 Department of Health and Human Services

8.

Novel Targeted Therapy for Breast Cancer

Amount: \$120,600.00

DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side eff ...

SBIR Phase I 2007 Department of Health and Human Services

9.

Development of a novel serum diagnosis for breast cancer

Amount: \$99,960.00

DESCRIPTION (provided by applicant): Each year 200,000 women in the US are diagnosed with breast cancer, and 40,000 women will die of the disease. Serum diagnosis for screening breast cancer patients ...

SBIR Phase I 2004 Department of Health and Human Services